查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016960

動物用藥品市場：2026-2032年全球市場預測（產品類型、給藥途徑、目標動物及通路分類）

Veterinary Drug Market by Product Category, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，動物用藥品市場價值將達到 487.2 億美元，到 2026 年將成長至 518.4 億美元，到 2032 年將達到 782.8 億美元，複合年成長率為 7.00%。

主要市場統計數據
基準年 2025 487.2億美元
預計年份：2026年 518.4億美元
預測年份 2032 782.8億美元
複合年成長率 (%) 7.00%

在不斷變化的獸醫保健格局中採取策略性行動：重點關注臨床、商業性和監管因素，這些因素要求產業採取果斷行動

現代動物用藥品產業正處於加速創新、日益嚴格的監管以及終端用戶需求不斷變化這三者交匯的階段。近年來，該行業的護理方法發生了演變，更加重視預防醫學、生物製藥以及更合理的抗生素使用。這些趨勢正在改變供應商和獸醫的行為，並促使投資在不同治療領域和劑型之間重新分配。

科學、監管和商業領域的重大變化正在重塑動物用藥品的優先事項，並重新定義如何為臨床醫生和飼主提供價值。

這些變革性的變化正在推動動物用藥品產業研發重點、製造地和經營模式的重組。隨著生物製藥和新一代疫苗的興起，人們對合理使用抗菌藥物的關注度再次提升，促使研發公司致力於開發窄頻譜藥物、替代療法以及用於指導治療的先進診斷工具。同時，供應鏈韌性、靈活的生產結構以及合約研發生產（CDMO）夥伴關係等營運轉型也在穩步推進，並逐漸成為核心能力。

2025 年不斷增加的關稅壓力促使供應鏈進行全面重新設計，製造地按地區轉移，籌資策略，以保障產品供應和獲利能力。

2025年實施的關稅調整進一步增加了採購、定價和跨境物流的複雜性，影響了產品供應和籌資策略。製造商和經銷商正在重新審視與供應商的合約以及運輸路線，以降低不斷上漲的收貨成本，並在不影響供貨的前提下維持利潤率。這些調整通常需要優先考慮短期庫存，並實現長期供應來源多元化，以降低集中採購帶來的風險。

從詳細的細分觀點，產品類型的交集揭示了差異化的機會。

精細的市場區隔技術清楚地揭示了治療需求與分銷複雜性之間的交匯點。依產品類型分析，市場包括感染疾病物、抗發炎藥物、驅蟲藥和疫苗。感染疾病物包括抗生素、抗真菌藥物和抗病毒藥物，其中抗生素細分為頭孢菌素類、Fluoroquinolones、大環內酯類、青黴素類和四環黴素。這種細緻的分類揭示了不同的創新路徑和合理用藥考量，這些因素會影響研發重點和標籤策略。

美洲、歐洲、中東和非洲以及亞太地區的戰略考量表明，每個地區的採用率、監管要求和分銷挑戰各不相同。

區域趨勢對有效的商業和監管策略至關重要。美洲市場的特點是擁有先進的獸醫臨床基礎設施、寵物擁有率高，以及對高品質生技藥品和診斷試劑日益成長的需求。這些特點有利於強勁的創新和新療法的早期上市。由於不同地區的政策和支付模式存在差異，因此在市場准入和報銷談判中需要採取細緻入微、因地制宜的方法。

為了在獸醫市場中超越競爭對手，競爭策略正在形成，其核心是綜合治療方法、數位服務、強大的供應鏈和證據生成。

隨著成熟的跨國動物用藥品公司不斷拓展產品線，競爭格局正在發生變化，專注於生技藥品、診斷和新型驅蟲藥的敏捷型專業公司應運而生。主要企業優先考慮整合治療方案，將治療藥物與數位支援工具、療效追蹤以及能夠增強獸醫和飼主互動體驗的服務相結合。策略合作和授權協議正被擴大用於加速新治療方法的推廣應用，並分散生技藥品和專科療法相關的研發風險。

為了確保永續的競爭優勢，經營團隊必須採取切實可行的策略行動，將合理使用抗菌藥物、區域生產和以通路為中心的商業化連結起來。

產業領導企業應優先採取一系列切實可行的措施，協調科學、供應和行銷，在掌握短期機會的同時，建構長期韌性。首先，推動合理抗菌藥物使用（AMS）工作，並配合標靶藥物藥物和診斷藥物的研發，能夠滿足不斷變化的監管要求和臨床醫生對更安全、循證治療方法的需求。其次，投資建立靈活的生產結構和區域生產能力，特別是針對關鍵生物製藥和疫苗，可以降低關稅和物流風險，並提高市場應對力。

採用嚴謹的混合方法研究途徑，結合關鍵相關人員的訪談、二手資訊和情境分析，來檢驗趨勢和策略意義。

本調查方法結合了定量和定性方法，以確保獲得可靠且可操作的洞見。第一階段包括對價值鏈上的關鍵相關人員進行結構化訪談，這些利益相關者包括臨床醫生、採購負責人和行業高管，旨在了解他們對臨床需求、處方集決定因素和分銷偏好的真實觀點。第二階段則利用監管文件、臨床文獻、專利申請和企業資訊披露來佐證趨勢並確定新興技術的部署路徑。

這項具有前瞻性的綜合分析概述了科學、營運和商業性策略的整合將如何決定獸醫治療領域的長期成功。

總之，在科學創新、法規演變和商業性格局變化的驅動下，動物用藥品產業正經歷一場意義深遠的變革時期。積極實踐合理使用抗菌藥物原則、投資建立穩健靈活的生產系統，並針對不同動物群體和分銷管道的獨特需求最佳化商業性策略的利益相關者，將更有利於獲得長期價值。區域相關人員仍然至關重要。美洲、歐洲、中東、非洲和亞太地區各自擁有獨特的監管、臨床和物流現實，在製定市場准入和擴大策略時必須認真考慮這些因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：動物用藥品市場：依產品類型

  • 抗感染藥物
    • 抗生素
      • 頭孢菌素
      • Fluoroquinolones
      • 大環內酯類
      • 青黴素
      • 四環黴素
    • 抗真菌藥物
    • 抗病毒藥物
  • 抗發炎藥
  • 殺蟲劑
  • 疫苗

第9章：動物用藥品市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服
  • 外用

第10章：動物用藥品市場：依目標動物分類

  • 水產養殖
    • 魚
    • 蝦
  • 伴侶動物
    • 狗
    • 貓
  • 馬
  • 家畜
    • 牛
    • 小反芻動物
    • 豬
  • 家禽
    • 雞
    • 火雞

第11章：動物用藥品市場：依通路分類

  • 網路藥房
  • 零售藥房
  • 動物醫院

第12章：動物用藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：動物用藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章動物用藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國：動物用藥品市場

第16章 中國：動物用藥品市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-034B50030391

The Veterinary Drug Market was valued at USD 48.72 billion in 2025 and is projected to grow to USD 51.84 billion in 2026, with a CAGR of 7.00%, reaching USD 78.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.72 billion
Estimated Year [2026] USD 51.84 billion
Forecast Year [2032] USD 78.28 billion
CAGR (%) 7.00%

A strategic introduction to the evolving veterinary therapeutics environment highlighting clinical, commercial, and regulatory forces that demand decisive industry responses

The contemporary veterinary drug landscape sits at the intersection of accelerating innovation, heightened regulatory scrutiny, and shifting end-user expectations. In recent years the industry has seen evolving modes of care that emphasize preventive health, biologics, and more nuanced antimicrobial stewardship. These dynamics are reshaping supplier and practitioner behavior, driving a rebalancing of investment across therapeutic classes and delivery formats.

As stakeholders adapt, the need for a clear strategic foundation becomes paramount. Veterinarians and industry leaders are navigating pressures from tighter regulations on antimicrobial use, rising demand for safer and more targeted therapies, and the operational realities of delivering care across diverse animal species and care settings. Moreover, the adoption of digital channels and telehealth has begun to influence how products are distributed and how owners access treatment options. Consequently, market participants must reassess portfolio priorities, manufacturing resilience, and engagement models with clinical end users to remain competitive.

Transitioning from observation to strategy requires synthesizing clinical trends with commercial realities. This introduction frames the essential forces shaping the field and sets the stage for deeper analysis on transformative shifts, tariff impacts, segmentation-driven opportunities, regional dynamics, competitive positioning, and practical recommendations for leaders seeking to translate insight into action.

High-impact scientific, regulatory, and commercial transformations are reshaping priorities in veterinary therapeutics and redefining how value is delivered to clinicians and owners

Transformative shifts are driving a reconfiguration of R&D priorities, manufacturing footprints, and commercial models within veterinary pharmaceuticals. The push toward biologics and next-generation vaccines has been accompanied by renewed attention to antimicrobial stewardship, prompting developers to pursue narrower-spectrum agents, alternative modalities, and enhanced diagnostic tools to guide therapy. These scientific trends are paralleled by operational transformations: supply chain resilience, flexible manufacturing, and the adoption of contract development and manufacturing partnerships are becoming core capabilities.

Commercially, channel dynamics are evolving as online pharmacies and digital platforms expand access while traditional veterinary hospitals remain central for clinical interventions. This digitization, combined with improved data capture at point of care, creates opportunities for outcomes-focused offerings and subscription-based preventative programs. Shifts in animal ownership patterns-such as higher investment in companion animal health-are altering demand mix across therapeutic categories and routes of administration, influencing formulary decisions and promotional strategies.

Regulatory frameworks and payer expectations are tightening, which compels companies to design evidence generation plans that demonstrate safety, efficacy, and real-world value. Collectively, these shifts require organizations to adopt integrated strategies that align scientific innovation with supply chain agility and commercial modernization to capture sustainable advantage.

Elevated tariff pressures in 2025 are prompting comprehensive supply chain redesigns, regional manufacturing shifts, and procurement strategies to safeguard access and margins

Tariff changes implemented in 2025 have introduced additional layers of complexity for sourcing, pricing, and cross-border logistics, affecting product availability and procurement strategies. Manufacturers and distributors are reassessing supplier contracts and transportation routes to mitigate increased landed costs and to preserve margins without compromising accessibility. These adjustments often necessitate near-term inventory prioritization and long-term supply base diversification to reduce exposure to concentrated sourcing risks.

In practice, the tariff environment has accelerated conversations around regional manufacturing and onshoring for critical inputs and finished products, particularly for essential classes such as anti-infectives and vaccines. Companies are also revisiting transfer pricing frameworks and distribution agreements to manage costs across geographies. For clinical stakeholders, the outcome is a heightened focus on formulary rationalization and therapeutic substitution where feasible, underpinned by a renewed emphasis on cost-effective, evidence-based therapy selection.

Looking ahead, tariffs are likely to remain a structural consideration in commercial planning, influencing decisions about where to invest in capacity, which partnerships to prioritize, and how to structure distribution networks to balance resilience with competitive pricing.

Deep segmentation perspectives reveal where product categories, administration routes, animal types, and distribution channels converge to create differentiated opportunities

A refined segmentation approach offers clarity on where therapeutic demand and distribution complexity converge. When analyzed by product category, the market encompasses anti-infectives, anti-inflammatories, parasiticides, and vaccines; within anti-infectives there are antibiotics, antifungals, and antivirals, and antibiotics can be further differentiated into cephalosporins, fluoroquinolones, macrolides, penicillins, and tetracyclines. This granularity reveals diverging innovation pathways and stewardship considerations that influence development priorities and labeling strategies.

Route of administration also shapes clinical adoption and commercial logistics, with inhalation, injectable, oral, and topical formats each presenting distinct formulation, storage, and administration constraints. Animal type segmentation shows differentiated demand drivers: aquaculture-comprising fish and shrimp-presents disease profiles and delivery challenges unlike those in companion animals, which include canines and felines; equine care emphasizes specialized therapeutics and dosing regimens; livestock, spanning cattle, small ruminants, and swine, requires scalable, cost-sensitive solutions; and poultry, represented by chickens and turkeys, demands approaches suited to mass administration and biosecurity.

Distribution channels further affect market access, where online pharmacies, retail pharmacies, and veterinary hospitals each offer unique customer touchpoints and compliance requirements. Synthesizing these segmentation lenses helps identify where product differentiation, targeted evidence, and tailored commercial models will deliver the greatest strategic return.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal differentiated adoption, regulatory, and distribution imperatives

Regional dynamics are central to effective commercial and regulatory strategy. In the Americas, markets are characterized by advanced veterinary clinical infrastructure, high companion animal ownership, and growing demand for premium biologics and diagnostics; these features support robust innovation and early adoption of novel therapeutics. Policies and payer models vary across the region, requiring nuanced approaches to market entry and reimbursement discussions.

Europe, Middle East & Africa present a heterogeneous landscape where stringent regulatory expectations in some markets coexist with emerging access challenges in others. Antimicrobial stewardship frameworks and harmonized safety standards are prominent in parts of Europe, while key growth opportunities may be found in markets with rising livestock intensity and expanding veterinary services. Meanwhile, supply chain considerations and import regulations in this region influence where localized manufacturing or distribution partnerships are most beneficial.

Asia-Pacific exhibits diverse demand drivers, from intensifying aquaculture production and large-scale livestock operations to rapidly expanding companion animal care in urban centers. Regulatory modernization, investments in cold chain infrastructure, and increasing digital adoption are reshaping how products are commercialized. Together, these regional insights suggest that tailored regulatory strategies, differentiated product positioning, and adaptive distribution models are essential for successful market penetration and sustainable growth.

Competitive strategies are coalescing around integrated therapeutics, digital services, resilient supply chains, and evidence generation to outpace peers in veterinary markets

Competitive positioning is evolving as incumbent multinational animal health companies expand their portfolios alongside nimble specialized players focused on biologics, diagnostics, and novel antiparasitic agents. Leading firms are prioritizing integrated solutions that combine therapeutics with digital support tools, outcomes tracking, and services that enhance veterinarian and owner engagement. Strategic collaborations and licensing agreements are increasingly used to accelerate access to novel modalities and to spread the development risk associated with biologics and specialty therapeutics.

Operational excellence remains a differentiator: companies that have invested in flexible manufacturing, robust quality systems, and resilient supply chains are better positioned to navigate tariff volatility and fluctuating demand across animal types. Equally important is the ability to generate and communicate high-quality clinical evidence that resonates with both regulatory bodies and practitioners. As the competitive landscape matures, firms that align product innovation with accessible delivery formats and compelling value propositions will secure advantage in both clinical preference and procurement decisions.

Practical strategic actions for leadership to synchronize antimicrobial stewardship, regional manufacturing, and channel-focused commercialization for sustained advantage

Industry leaders should prioritize a set of actionable moves that align science, supply, and sales to capture near-term opportunities while building long-term resilience. First, advancing antimicrobial stewardship initiatives alongside development of targeted agents and diagnostics will meet evolving regulatory expectations and clinician demand for safer, evidence-based therapies. Second, investing in flexible manufacturing and regional capacity-especially for critical biologics and vaccines-will mitigate tariff and logistics exposure and accelerate market responsiveness.

Commercially, tailoring offerings by combining therapeutics with digital adherence tools and practice-level support will strengthen relationships with veterinary hospitals and differentiate products sold through online and retail pharmacies. Segment-focused strategies should recognize that companion animal owners prioritize convenience and advanced care, whereas livestock and poultry customers emphasize affordability, ease of administration, and scalability. Finally, leaders should adopt agile pricing and distribution models informed by regional regulatory landscapes and local channel economics to maintain competitiveness while preserving clinical choice.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary intelligence, and scenario analysis to validate trends and strategic implications

The research methodology blends quantitative and qualitative approaches to ensure robust, actionable findings. Primary research involved structured interviews with key stakeholders across the value chain, including clinical practitioners, procurement specialists, and industry executives, to capture real-world perspectives on clinical needs, formulary drivers, and distribution preferences. Secondary research incorporated regulatory documents, clinical literature, patent filings, and company disclosures to corroborate trends and identify emerging technology pathways.

Analytical frameworks applied include segmentation analysis across product categories, routes of administration, animal types, and distribution channels to reveal demand patterns and operational constraints. Scenario analysis was used to stress-test supply chain and tariff sensitivities, while cross-regional comparisons illuminated regulatory and commercial variances. Data quality controls and triangulation methods were employed throughout to validate insights, and findings were peer-reviewed by subject matter experts with clinical and commercial experience in veterinary therapeutics.

A forward-looking synthesis outlining how integrated scientific, operational, and commercial strategies will determine long-term success in veterinary therapeutics

In conclusion, the veterinary drug landscape is undergoing a period of substantive change driven by scientific innovation, regulatory evolution, and shifting commercial dynamics. Stakeholders who proactively integrate antimicrobial stewardship principles, invest in resilient and flexible manufacturing, and tailor commercial approaches to the unique needs of each animal segment and distribution channel will be best positioned to capture long-term value. Regional nuance remains a decisive factor: the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct regulatory, clinical, and logistical realities that must inform market entry and expansion strategies.

Ultimately, the most successful organizations will be those that translate insight into coordinated execution-aligning R&D priorities with practical deployment plans, building partnerships that accelerate access to novel modalities, and deploying commercial models that resonate with practitioners and owners. This synthesis of clinical credibility, operational strength, and commercial agility defines the pathway to sustainable success in the evolving veterinary therapeutics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Drug Market, by Product Category

  • 8.1. Anti-Infectives
    • 8.1.1. Antibiotics
      • 8.1.1.1. Cephalosporins
      • 8.1.1.2. Fluoroquinolones
      • 8.1.1.3. Macrolides
      • 8.1.1.4. Penicillins
      • 8.1.1.5. Tetracyclines
    • 8.1.2. Antifungals
    • 8.1.3. Antivirals
  • 8.2. Anti-Inflammatories
  • 8.3. Parasiticides
  • 8.4. Vaccines

9. Veterinary Drug Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Veterinary Drug Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animals
    • 10.2.1. Canines
    • 10.2.2. Felines
  • 10.3. Equine
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Small Ruminants
    • 10.4.3. Swine
  • 10.5. Poultry
    • 10.5.1. Chickens
    • 10.5.2. Turkeys

11. Veterinary Drug Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Hospitals

12. Veterinary Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Veterinary Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Veterinary Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Veterinary Drug Market

16. China Veterinary Drug Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Boehringer Ingelheim International GmbH
  • 17.6. Ceva Sante Animale S.A.
  • 17.7. Dechra Pharmaceuticals PLC
  • 17.8. Elanco Animal Health Incorporated
  • 17.9. Merck & Co., Inc.
  • 17.10. Norbrook Laboratories Limited
  • 17.11. Phibro Animal Health Corporation
  • 17.12. Vetoquinol S.A.
  • 17.13. Virbac S.A.
  • 17.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. GCC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 215. GCC VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. GCC VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 221. GCC VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. G7 VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. G7 VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 254. G7 VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. NATO VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 258. NATO VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 259. NATO VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. NATO VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 265. NATO VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)